Table 2 Adverse Events
Group | Event | 3mo | 6mo | 9mo | 12mo |
|---|---|---|---|---|---|
0.1% loading dose | Total events, N/total N (%) | 22/33 (66%) | 15/33 (45%) | 6/33 (18%) | 2/33 (6%) |
Eye redness/irritation, N/total N (%) | 3/33 (9%) | 2/33 (6%) | 0/33 (0%) | 1/33 (3%) | |
Photophobia, N/total N (%) | 16/33 (48%) | 11/33 (33%) | 2/33 (6%) | 0/33 (0%) | |
Blurred near vision, N/total N (%) | 18/33 (55%) | 12/33 (36%) | 1/33 (3%) | 1/33 (3%) | |
Blurred distance vision, N/total N (%) | 0/33 (0%) | 0/33 (0%) | 0/33 (0%) | 0/33 (0%) | |
Other, N/total N (%) | 3/33 (9%) | 2/33 (6%) | 2/33 (6%) | 0/33 (0%) | |
Dilated pupils, N/total N (%) | 11/33 (33%) | 7/33 (21%) | 1/33 (3%) | 0/33 (0%) | |
0.01% | Total events, N/total N (%) | 8/32 (25%) | 1/32 (3%) | 1/32 (3%) | 1/32 (3%) |
Eye redness/irritation, N/total N (%) | 2/32 (6%) | 1/32 (3%) | 1/32 (3%) | 0/32 (0%) | |
Photophobia, N/total N (%) | 3/32 (9%) | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | |
Blurred near vision, N/total N (%) | 0/32 (0%) | 1/32 (3%) | 0/32 (0%) | 1/32 (3%) | |
Blurred distance vision, N/total N (%) | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | |
Other, N/total N (%) | 5/32 (16%) | 0/32 (0%) | 0/32 (0%) | 1/32 (3%) | |
Dilated pupils, N/total N (%) | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) | |
Placebo | Total events, N/total N (%) | 6/32 (19%) | 4/31 (13%) | 1/30 (3%) | 1/29 (3%) |
Eye redness/irritation, N/total N (%) | 2/32 (6%) | 2/31 (6%) | 1/30 (3%) | 0/29 (0%) | |
Photophobia, N/total N (%) | 0/32 (0%) | 0/31 (0%) | 0/30 (0%) | 0/29 (0%) | |
Blurred near vision, N/total N (%) | 0/32 (0%) | 0/31 (0%) | 0/30 (0%) | 1/29 (3%) | |
Blurred distance vision, N/total N (%) | 0/32 (0%) | 0/31 (0%) | 0/30 (0%) | 0/29 (0%) | |
Other, N/total N (%) | 4/32 (13%) | 3/31 (10%) | 0/30 (0%) | 1/29 (3%) | |
Dilated pupils, N/total N (%) | 0/32 (0%) | 0/31 (0%) | 0/30 (0%) | 0/29 (0%) |